RHÖN-KLINIKUM Full Year 2024 Earnings: Beats Expectations

Simply Wall St

March 28, 2025

RHÖN-KLINIKUM (ETR:RHK) Full Year 2024 Results

Key Financial Results

Revenue: €1.87b (up 7.7% from FY 2023).
Net income: €43.4m (up 12% from FY 2023).
Profit margin: 2.3% (up from 2.2% in FY 2023). The increase in margin was driven by higher revenue.
EPS: €0.65 (up from €0.58 in FY 2023).

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

earnings-and-revenue-growth — XTRA:RHK Earnings and Revenue Growth March 28th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

RHÖN-KLINIKUM Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.6%.

Looking ahead, revenue is expected to decline by 7.9% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.0%.

Performance of the German Healthcare industry.

The company's shares are up 4.6% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of RHÖN-KLINIKUM's balance sheet and an in-depth analysis of the company's financial position.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.